** Shares of drug developer Tevogen Bio rise as much as 84.5% to an over six-month high of $2.97
** Co says its artificial intelligence effort, Tevogen AI, has partnered with Microsoft under Microsoft for Startups program
** TVGN says the partnership will provide it with access to MSFT's extensive ecosystem
** "The partnership is set to accelerate and streamline the development of Tevogen’s proprietary algorithms, significantly advancing our mission to lower the total cost of drug development, expedite drug discovery" - co
** According to McKinsey Global Institute, generative AI could generate $60 bln-$110 bln annually in economic value for pharma and medtech companies, with $18-$30 billion of that value attributed to commercial functions alone - TVGN
** Tevogen AI's chief information officer, Mittul Mehta, used to work at MSFT
** YTD, TVGN stock down 78%
(Reporting by Puyaan Singh)
((Puyaan.Singh@thomsonreuters.com;))
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.